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Elephantopus mollis (EM) is a traditional herbal medicine with multiple pharmacological
activities. However, the efficacy of EM in treating human leukemia is currently unknown.
In the current study, we report that EM23, a natural sesquiterpene lactone isolated
from EM, inhibits the proliferation of human chronic myeloid leukemia (CML) K562 cells
and acute myeloid leukemia (AML) HL-60 cells by inducing apoptosis. Translocation of
membrane-associated phospholipid phosphatidylserines, changes in cell morphology,
activation of caspases, and cleavage of PARP were concomitant with this inhibition.
The involvement of the mitochondrial pathway in EM23-mediated apoptosis was
suggested by observed disruptions in mitochondrial membrane potential. Mechanistic
studies indicated that EM23 caused a marked increase in the level of reactive oxygen
species (ROS). Pretreatment with N-acetyl-L-cysteine, a ROS scavenger, almost fully
reversed EM23-mediated apoptosis. In EM23-treated cells, the expression levels of
thioredoxin (Trx) and thioredoxinreductase (TrxR), two components of the Trx system
involved in maintaining cellular redox homeostasis, were significantly down-regulated.
Concomitantly, Trx regulated the activation of apoptosis signal-regulating kinase 1
(ASK1) and its downstream regulatory targets, the p38, JNK, and ERK MAPKs. EM23-
mediated activation of ASK1/MAPKs was significantly inhibited in the presence of NAC.
Furthermore, tumor necrosis factor alpha (TNF-α)-mediated activation of nuclear factor-
κB (NF-κB) was suppressed by EM23, as suggested by the observed blockage of
p65 nuclear translocation, phosphorylation, and reversion of IκBα degradation following
EM23 treatment. Taken together, these results provide important insights into the
anticancer activities of the EM component EM23 against human CML K562 cells and
AML HL-60 cells.
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INTRODUCTION
Leukemia, a malignant disease affecting blood cells, usually
begins in the bone marrow and is characterized by an aberrant
accumulation of abnormal white blood cells. Leukemia can be
clinically and pathologically subdivided into four main types:
acute lymphoblastic leukemia (ALL), acute myeloid leukemia
(AML), chronic lymphocytic leukemia (CLL), and chronic
myeloid leukemia (CML), as well as many less common types
(Vardiman et al., 2009). The treatment of leukemia is complicated
and is influenced by the age and overall health of an affected
patient as well as by their type of leukemia, in addition to
other factors. However, chemotherapy remains one of the major
therapeutic approaches for leukemia.
Both AML and CML are myeloid or myelogenous leukemias,
and the initial cancerous changes associated with these
cancers affect certain blood-forming cells in the bone marrow.
Currently, bone marrow transplantation/allogeneic stem cell
transplantation is the only curative treatment for CML
(Goldman et al., 2010). TKIs that target BCR-ABL are the
standard treatment for CML. Imatinib mesylate, a first-
generation TKI (Kantarjian et al., 2002), has produced excellent
clinical results in terms of achieving high remission rates
and improving prognosis (Hughes et al., 2006; Bhamidipati
et al., 2013). New second- and third- generation TKIs, such as
dasatinib, nilotinib, and bosutinib, exhibit superior inhibitory
activity against BCR-ABL compared to imatinib. Although
TKIs are extensively used, serious drug-drug interactions and
emerging resistance of CML cells to TKIs through multiple
mechanisms has limited their clinical application (Volpe et al.,
2009).
AML is the most common acute leukemia in adult patients.
This type of leukemia progresses rapidly and may be lethal within
weeks or months. Based on the cytogenetic/genetic features of
AML, and according to the 2008 revised WHO classification
system, patients can be broadly classified into three different
risk groups. Treatment strategies and prognoses vary among
these subtypes and are further influenced by patient-specific
factors (Grimwade et al., 2010; Zeisig et al., 2012). All AML
subtypes, except for acute promyelocytic leukemia (APL), are
typically treated with induction chemotherapy using a “3+7”
combination of daunorubicin and cytarabine (Dohner et al.,
2010; Zeisig et al., 2012). Treatment with all-trans retinoic
acid, which can effectively induce APL cell differentiation, can
achieve complete remission in almost all APL patients (Degos
and Wang, 2001). Conversely, although treatment strategies for
AML have substantially progressed in recent decades, effective
therapies for non-APL subtypes of AML are still urgently needed.
Abbreviations: ASK1, apoptosis regulating-signal kinase 1; CCK-8, Cell
Counting Kit-8; DAPI, 4′,6-diamidino-2-phenylindole; DCFH-DA, 2’,7’-
dichlorofluorescein diacetate; DMSO, dimethyl sulfoxide; EM, Elephantopus
mollis; JC-1, 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethyl-imidacarbocyanine iodide;
MAPK, mitogen-activated protein kinases; MMP, mitochondrial membrane
potential; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide;
NAC, N-acetyl-L-cysteine; NF-κB, nuclear factor-κB; PI, propidium iodide; ROS,
reactive oxygen species; TKIs, tyrosine kinase inhibitors; TNF-α, tumor necrosis
factor alpha; Trx, thioredoxin; TrxR, thioredoxinreductase; TUNEL, terminal
deoxynucleotidyltransferase-mediated dUTP nick-end labeling.
Tumor cells usually have a more active metabolism than
normal cells to maintain their rapid growth and escape from cell
death (Hanahan and Weinberg, 2011). Leukemia cells undergo
many pathological changes compared to normal blood cells.
Therefore, the identification of phytocompounds from medicinal
or edible plants that affect multiple intracellular targets may lead
to the discovery of a novel, effective and multifunctionalanti-
leukemia drug or prodrug.
Elephantopus mollis (EM) belongs to the Asteraceae family
and is used as a folk medicine in China. EM possesses
multiple pharmacological activities, including anticancer activity
(Tabopda et al., 2008; Ooi et al., 2011, 2012), anti-protozoal
activity (Gachet et al., 2010), melanogenesis inhibition activity
(Hasegawa et al., 2010), bone regenerative activity (Ngueguim
et al., 2012), and hepatoprotective activity (Lin et al., 1995).
However, whether EM is an efficacious treatment option for
human AML and CML remains unknown.
In this study, we investigated the anti-leukemia properties
and associated molecular mechanisms of EM23, a natural
sesquiterpene lactone isolated from EM, in the K562 and
HL-60 human CML and AML cell lines. Mechanistically, we
demonstrated that EM23 inhibited the mammalian Trx system,
interfered with cellular redox homeostasis and resulted in ROS-
dependent apoptosis by regulating complex signaling pathways,
including those governed by ASK1, MAPK, and NF-κB.
MATERIALS AND METHODS
Cell Culture and Reagents
The human CML cell line K562, the human APL cell line
HL-60, human liver cell line HL-7702 and mouse embryonic
fibroblast cell line NIH/3T3 (NIH/swiss) were obtained from
the Cell Bank of the Chinese Academy of Sciences (Shanghai,
China). K562 and HL-60 cells were cultured in RPMI 1640
medium (Life Technologies, Grand Island, NY, USA). HL-7702
and NIH/3T3 cells were grown in DMEM medium (Life
Technologies, Grand Island, NY, USA). All cell lines were grown
in specific media supplemented with 10% fetal bovine serum
(FBS, Gibco), 100 U/mL penicillin and 100 µg/mL streptomycin
(Invitrogen, Carlsbad, CA, USA). The cells were grown in a 5%
CO2 humidified atmosphere in incubators maintained at 37◦C.
EM23 (Figure 1A) was isolated and purified from EM by
our group. The chemical structure of EM23 was identified by
1H-NMR and 13C-NMR spectra data as described in our previous
study (Liang et al., 2012). A stock solution of EM23 was dissolved
in DMSO at concentration of 100 mM and diluted to the
indicated final concentration in culture medium. DMSO was
diluted to 0.1% in medium as a vehicle control.
The reagents DAPI, DCFH-DA, PI, JC-1, and NAC were
purchased from Sigma Chemical Co. (St. Louis, MO, USA).
ERK inhibitor FR180204 was purchased from Merck Millipore
(Bellerica, MA, USA). A PierceTM BCA Protein Assay Kit was
obtained from Thermo Fisher Scientific (Rockford, IL, USA).
TNF-α was obtained from Sino Biological Inc. (Beijing, China).
A CCK-8, a TUNEL Apoptosis Detection Kit, dithiothreitol
(DTT), a Nuclear and Cytoplasmic Extraction Kit, RIPA buffer
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FIGURE 1 | EM23 inhibits cell proliferation and cell cycle progression. (A) Chemical structure of EM23. (B) Effects of EM23 on human myeloid leukemia cell
proliferation. K562 and HL-60 cells were treated with various concentrations of EM23 for 48 and 72 h, respectively. Cell viability was measured using a CCK-8 assay.
(C) Cytotoxic effects of EM23 on normal mammalian cells. HL-7702 and NIH/3T3 cells were treated with various concentrations of EM23 for 48 h. Cell viability was
measured using a CCK-8 assay. (D) Effects of EM23 on cell cycle distribution. Following treatment with EM23 for 48 h, cells were fixed and stained with PI solution.
Cell cycle distribution was measured by flow cytometry. All of data are presented as the mean ± SD of at least three independent experiments. ∗P < 0.05 and
∗∗P < 0.01.
and RNase were purchased from Beyotime (Shanghai, China).
Phosphatase inhibitor cocktail tablets and protease inhibitor
cocktail tablets were supplied by Roche (Mannheim, Germany).
All other chemicals and solvents were of reagent or HPLC
grade.
Primary antibodies against TrxR, Trx, ASK1, p-ASK1
(Thr845), and Lamin B1 were purchased from Santa Cruz
Biotechnology (Dallas, TX, USA). GAPDH, β-actin, caspase 3,
caspase 9, cleaved-caspase 3, cleaved-caspase 9, cleaved PARP,
p-p38 (Thr180/Tyr182), p-ERK1/2 (Thr202/Tyr204), p-JNK
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(Thr183/Tyr185), p38, ERK1/2, JNK, p-NF-κB p-p65 (Ser536),
NF-κB p65, IκBα, anti-mouse, and anti-rabbit horseradish
peroxidase-conjugated secondary antibodies were purchased
from Cell Signaling Technology (CST, Beverly, MA, USA).
Alexa Fluor R© 568 phalloidin and Alexa Fluor R© 488 anti-rabbit
fluorescent secondary antibodies were purchased from Life
Technologies (Grand Island, NY, USA).
Cell Proliferation Analysis
A CCK-8 assay was used to detect EM23-mediated inhibition
of cellular proliferation. Cells in suspension were plated in 96-
well plates at a density of 1 × 104 cells/well. Following this, the
cells were treated with either vehicle (0.1% DMSO) or EM23.
The highest concentration of EM23 used was 100 µM; additional
concentrations were tested following two-fold serial dilutions.
The cells were treated for 48 h and then 10 µL CCK-8 solution
was added to each well, and the plate was incubated for an
additional 4 h. The absorbance of the plate was measured at
450 nm using a microplate reader (Bio-Rad; Hercules, CA, USA),
and the IC50 values for the different treatment conditions were
calculated using Origin 8 software (OriginLab, Northampton,
MA, USA).
Cell Cycle Analysis
K562 (2 × 105 cells/mL) and HL-60 (3 × 105 cells/mL) cells
were seeded into 6-well plates and then treated with vehicle or
EM23 for 48 h. Following this, the cells were collected, washed
twice with PBS, and fixed in cold 70% ethanol (–20◦C) overnight.
The ethanol was then carefully removed by centrifugation to
avoid cell loss, and the cells were resuspended in 1 mL staining
reagent (100 mg/mL RNase and 50 mg/mL PI) and kept in
darkness for 35 min at room temperature. Cell cycle analysis was
accomplished using flow cytometry (BD FACSCalibur, Franklin
Lakes, CA, USA) with a wave length of 605 nm.
Apoptosis Detection via Annexin-V-
FITC/PI Assay
K562 (2 × 105 cells/mL) and HL-60 (3 × 105 cells/mL) cells
were plated in 6-well plates during the log phase of growth and
then treated with either vehicle or the indicated concentrations of
EM23 for 48 h. The treated cells were harvested by centrifugation
at room temperature and washed twice with ice-cold PBS.
Following this, the cells were stained with Annexin-V-FITC/PI
(KeyGEN; Nanjing, China) according to the manufacturer’s
instructions and analyzed via flow cytometry.
Western Blotting Analysis
K562 and HL-60 cells were harvested and washed with PBS
after treatment with EM23 according to the specific experimental
design. Following this, the cells were lysed in RIPA buffer
containing 0.5 M DTT, 0.1 M PMSF, 20× protease inhibitor
cocktail, and 20× phosphatase inhibitor cocktail for 30 min
on ice, and then centrifuged at 12000 g at 4◦C for 15 min.
The resultant supernatants, which contained total cellular
protein, were collected, and nuclear proteins were extracted
using a nuclear and cytoplasmic extraction kit. The protein
concentration was measured using a BCA protein assay kit.
Equal amounts of protein (30 µg) were separated via 10–
15% gradient SDS-PAGE and transferred to PVDF membranes
(Millipore, USA). The membranes were blocked with 5% BSA
at room temperature for 1 h, incubated with primary antibodies
for at least 16 h at 4◦C, and then washed and incubated
with HRP-conjugated secondary antibodies at room temperature
for 1 h. Protein bands were visualized using enhanced
chemiluminescence detection reagents (Bio-Rad, USA). The
resulting images were scanned using a scanner (Epson V330
Photo, Japan).
TUNEL and DAPI Co-staining
K562 and HL-60 cells were treated with either vehicle or EM23
for 48 h, collected into Eppendorf tubes, and washed twice with
PBS. Following 4% paraformaldehyde fixation, the cells were
permeabilized with 0.2% Triton X-100 in PBS. Next, the cells were
stained with TUNEL reaction mixture and DAPI, after which
they were washed again with ice-cold PBS. The stained cells
were resuspended to a specific cell density and examined under
a confocal laser scanning microscope (Zeiss LSM 510, Germany)
for evidence of nuclear fragmentation.
Immunofluorescent Cell Staining
K562 (2× 105 cells/mL) and HL-60 (3× 105 cells/mL) cells were
seeded in 6-well plates and then co-treated with vehicle or EM23
with or without TNF-α (1 ng/mL) for 1 h. Following this, the
cells were collected, and subsequent operations were performed
in Eppendorf tubes. First, the cells were washed with ice-cold
PBS. Following this, the cells were fixed in 4% paraformaldehyde
for 15 min at room temperature and permeabilized with 0.2%
Triton X-100 in PBS. After being rinsed with PBS, the cells were
blocked with 5% BSA and incubated with an anti-p65 primary
antibody and an anti-rabbit fluorescent secondary antibody.
Following this, the cells were counterstained with phalloidin
and DAPI, washed again with ice-cold PBS and resuspended
to a specific cell density. To visualize the nuclear translocation
of p65, the above-treated cells were placed into a confocal
35-mm clear cover glass-bottom petri-dish and then viewed
and photographed using a confocal laser scanning microscope.
The collected images were processed using the manufacturer’s
software.
Evaluation of MMP
Mitochondrial membrane potential was measured using JC-1 dye
according to the manufacturer’s instructions. Cells treated with
the indicated experimental conditions were harvested and then
incubated with JC-1 dye (10 µg/mL) in the dark for 20 min at
37◦C. Following this, the cells were washed with ice-cold PBS and
analyzed by flow cytometry.
Determination of Cellular ROS
Generation
Intracellular ROS levels were measured using a DCFH-DA
assay after EM23 treatment. Briefly, after treatment with EM23
for1–4 h, K562, and HL-60 cells were incubated with 10 µM
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FIGURE 2 | EM23 induced cell apoptosis. (A) Effects of EM23 on the induction of apoptosis as measured by flow cytometry. K562 and HL-60 cells were treated
with EM23 for 48 h, and the apoptotic cell rate was analyzed after Annexin-V-FITC/PI staining. The data are presented as the mean ± SD of three independent
experiments. ∗P < 0.05 and ∗∗P < 0.01. (B) Representative images of DNA fragmentation and nuclear condensation in K562 and HL-60 cells exposed to EM23.
Nuclei were detected by TUNEL and DAPI staining. All images shown are representative of three independent experiments. (C) Western blotting analysis of caspase
9, cleaved caspase 9, caspase 3, cleaved caspase 3, and cleaved PARP (89 kDa) expression; β-actin served as an internal control. The data shown are
representative of three independent experiments.
DCF-DA at 37◦C for 30 min and then washed twice and
resuspended in PBS. Fluorescence intensity was measured by flow
cytometry, and the percentages of fluorescence-positive cells were
proportional to the ROS levels within the cell cytosol.
Statistical Analysis
All data are expressed as the mean ± standard deviation (SD)
of three independent experiments. Statistical significance was
assessed using Student’s t-test (for comparisons of two treatment
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FIGURE 3 | EM23 interfered with cellular redox homeostasis. (A) Flow cytometry analysis of MMP based on JC-1 staining. Cells were treated with EM23 for
48 h and stained with JC-1. The cells showing a loss of MMP were gated. Cells were exposed to the MMP disrupter carbonyl cyanide 3-chlorophenylhydrazone
(CCCP, 10 µM) for 20 min as a positive control. All data are presented as the mean ± SD of three independent experiments. ∗P < 0.05 and ∗∗P < 0.01. (B) EM23
induced ROS production in K562 and HL-60 cells. Cells were treated with 2 µM EM23 for 1–4 h, stained with DCFH-DA for 20 min, and analyzed for fluorescence
by flow cytometry. All data are presented as the mean ± SD of three independent experiments. ∗P < 0.05 and ∗∗P < 0.01. (C) Effects of EM23 on the expression
levels of Trx and TrxR. K562 and HL-60 cells were treated with EM23 for 48 h and then subjected to western blotting. β-actin was used as an internal control. The
data shown are representative of three independent experiments.
groups) or one-way ANOVA (for comparisons of three or more
groups). P-values< 0.05 were considered statistically significant.
RESULTS
EM23 Inhibits the Proliferation of K562
and HL-60 Leukemia Cells
The chemical structure of EM23 is shown in Figure 1A. A CCK-8
assay was used to evaluate the ability of EM23 to inhibit leukemia
cell proliferation. Figure 1B shows that EM23 suppressed the
proliferation of K562 and HL-60 cells in a dose-dependent
manner. After 48 h of treatment with EM23, the IC50 values for
K562 and HL-60 cells were 10.8 and 1.9 µM, respectively. When
the treatment time was extended to 72 h, EM23 showed more
significant proliferation inhibitory activities, with IC50 values of
6.3 and 1.4 µM for K562 and HL-60 cells, respectively.
We also examined the effects of EM23 on the proliferation
of normal mammalian HL-7702 and NIH/3T3 cells. As shown
in Figure 1C, EM23 exhibited lower proliferation inhibitory
activities in HL-7702 and NIH/3T3 cells as compared to those
in K562 and HL-60 leukemia cells. The IC50 values of EM23 for
HL-7702 and NIH/3T3 cells were 40.4 and 25.6 µM, respectively,
which were approximately 4-fold and 2-fold higher than that of
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FIGURE 4 | Continued
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FIGURE 4 | Continued
NAC reversed EM23-mediated apoptosis and cells accumulation.
(A) The induction of apoptosis in K562 and HL-60 cells following treatment
with EM23 was rescued following treatment with NAC. K562 and HL-60 cells
were pretreated with 5 mM NAC for 1 h, followed by treatment with 8 and 4 µM
EM23 for 48 h, respectively. Next, the treated cells were stained with Annexin-
V-FITC/PI and analyzed by flow cytometry. All data are presented as the
mean ± SD of three independent experiments. Bars with different characters
indicate significant differences. ∗P< 0.05 and ∗∗P< 0.01 compared to control;
#P < 0.05 and ##P < 0.01 compared to NAC+EM23. (B) NAC inhibited EM23-
mediated cell cycle redistribution. K562 and HL-60 cells were pretreated with
5 mM NAC for 1 h, followed by treatment with 8 and 4 µM EM23 for 48 h,
respectively. The cell cycle phase distributions of the EM23-treated cells were
analyzed by flow cytometry. All data are presented as the mean ± SD of three
independent experiments. Bars with different characters indicate significant
differences. ∗P < 0.05 and ∗∗P < 0.01 compared to control; #P < 0.05 and
##P < 0.01 compared to NAC+EM23. (C) NAC reduced the morphological
changes caused by EM23. K562 and HL-60 cells were treated with 16
and 8 µM, respectively, and then subjected to TUNEL-DAPI co-staining and
examined under a confocal laser scanning microscope. All images shown are
representative of three independent experiments that produced similar results.
for K562 cells, and 21-fold and 13-fold higher than that of for
HL-60 cells, respectively. In addition, the rate of cell viability was
above 85% when HL-7702 and NIH/3T3 cells were treated with
EM23 at 8 µM for 48 h.
EM23 Delays Cell Cycle Progression in
K562 and HL-60 Cells
To elucidate whether EM23-mediated decreases in K562
and HL-60 cell proliferation were associated with changes
in cell cycle progression, the cell cycle phase distributions
of EM23-treated cells were analyzed by flow cytometry. As
shown in Figure 1C, treatment with increasing concentrations
of EM23 for 48 h decreased the G0/G1 phase DNA content
from 42.6 to 35.6%, whereas the G2/M DNA content
increased from 5.1 to 12.5% in K562 cells, which dose-
dependently accumulated the cells in G2/M phase. In HL-60
cells, treatment with 4 µM EM23 increased the number
of cells in S phase by 29.5%, while the number of cells in
G0/G1 phase decreased by 23.1% compared with the control
(Figure 1D).
EM23 Induces Apoptosis and Caspase
Activation in K562 and HL-60 Cells
To further investigate the role of EM23 in the induction of
apoptotic cell death, K562 and HL-60 cells were treated with the
indicated concentrations of EM23 for 48 h, and cell apoptosis
was assessed via Annexin-V-FITC/PI FACS analysis. Notably,
both cell lines showed significant dose-dependent increases in
apoptosis ratios following treatment with EM23 (Figure 2A).
At an EM23 concentration of 8 µM, the apoptosis ratios were
62.6% for K562 cells. In HL-60 cells, treatment with 4 µM EM23
increased the percentage of apoptotic cells by 46.5% compared
with the control (Figure 2A). Furthermore, TUNEL-DAPI co-
staining revealed that the EM23-treated cells exhibited enhanced
apoptotic features, such as DNA fragmentation and nuclear
condensation (Figure 2B).
We next analyzed caspase activation and PARP cleavage in
EM23-treated cells. As shown in Figure 2C, the levels of initiator
caspases 9 and 3 significantly decreased as the concentration of
EM23 increased. Additionally, the levels of cleaved caspase 9
and 3 dose-dependently increased with EM23 treatment. PARP, a
DNA-repair enzyme, serves as a substrate for caspase 3 (Mullen,
2004). We next examined PARP degradation following EM23
treatment. As shown in Figure 2C, EM23 treatment led to specific
proteolytic cleavage of PARP, as indicated by the presence of 116
to 89 kDa PARP fragments in K562 and HL-60 cells. These results
suggest that caspase activation and PARP cleavage may underlie
EM23-mediated apoptosis in K562 and HL-60 cells.
EM23 Induces a Loss in MMP
The loss of MMP (1ψm) is a vital cellular event during the
process of intrinsic apoptosis. Therefore, we measured variations
in1ψm using a JC-1 MMP assay to monitor mitochondrial status
in EM23-treated K562 and HL-60 cells. As shown in Figure 3A,
EM23 treatment clearly disrupted 1ψm in both cell lines in a
dose-dependent manner. The proportions of green-fluorescent
cells within K562 and HL-60 cell populations increased by 36.2
and 55.5%, respectively, following treatment with 8 and 4 µM
EM23, demonstrating that EM23 led to MMP disruption in both
cell lines.
EM23 Increases Cellular ROS Levels and
Suppresses Trx System
To investigate whether EM23-mediated apoptosis was related to
the presence of ROS, we examined intracellular ROS production
in EM23-treated K562 and HL-60 cells using the fluorescent
probe DCFH-DA. As shown in Figure 3B, compared to the
control, intracellular ROS levels increased by over twofold in both
cell lines following exposure to EM23 for 2 h, indicating that ROS
accumulation occurred in both K562 and HL-60 cells in response
to treatment with EM23. Interestingly, continuous incubation
with EM23 for 4 h led to decreased ROS levels in both cell lines
relative to those measured after 2 h of treatment.
To further investigate the role of ROS generation in EM23-
mediated apoptosis, both cell lines were pretreated with the
ROS scavenger NAC. Flow cytometry analysis demonstrated
that EM23-mediated apoptosis and accumulation of cells in
G2/M or S phase were almost entirely rescued by NAC
(Figures 4A,B). As shown in Figure 4C, pretreatment with NAC
also significantly inhibited EM23-mediated DNA fragmentation
and nuclear condensation based on TUNEL-DAPI co-staining.
These results suggest that ROS accumulation was required
for apoptotic cell death in EM23-treated K562 and HL-60
cells.
The Trx system, one of the major intracellular antioxidant
systems, is integral for maintaining a balanced intracellular redox
state (Collet and Messens, 2010). The effects of EM23 on Trx
and TrxR expression were examined in K562 and HL-60 cells.
As shown in Figure 3C, the expression levels of both Trx and
TrxR were dose-dependently down-regulated by EM23 in K562
and HL-60 cells. These results suggest that EM23 may increase
cellular ROS levels by inhibiting the Trx system.
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FIGURE 5 | Effects of EM23 on ASK1 and p38/JNK/ERK MAPK activation. (A) K562 and HL-60 cells were treated with 0, 2, 4, and 8 µM EM23 for 48 h or
treated with 8 µM EM23 for 0, 0.5, 1, 3, 6, and 12 h. The expression levels of ASK1 and p-ASK1 were analyzed by western blotting analysis. β-actin was used as an
internal control. (B) K562 and HL-60 cells were exposed to 8 µM EM23 for 0, 0.5, 1, 3, 6, and 12 h and then the phosphorylation levels of p38, JNK, and ERK1/2
were detected by western blotting. All protein levels were normalized to the level of β-actin. The data shown are representative of three independent experiments.
(C) Effects of ERK inhibitor FR180204 on EM23-mediated proliferation inhibitory activities. K562 and HL-60 cells were pre-treated with 5 and 2.5 µM FR180204,
respectively. Then the cells were incubated with various concentrations of EM23 for 48 h. Cell viability was measured using a CCK-8 assay. The data shown are the
mean ± SD of at least three independent experiments. ∗P < 0.05 and ∗∗P < 0.01.
ASK1- and MAPK-Mediated Signaling
Pathways in EM23-Treated Cells
ASK1 is activated by various types of stress, including the
accumulation of ROS. The reduced form of Trx is an endogenous
inhibitor of ASK1. When Trx is oxidized, it dissociates from
ASK1, which is then activated by the autophosphorylation
of Thr845 in its kinase domain, leading to the downstream
activation of the JNK and p38 MAPK pathways (Lu and
Holmgren, 2012). As shown in Figure 5A, EM23 activated
endogenous ASK1 through the phosphorylation of its Thr845
residue in a time-dependent and dose-dependent manner in
K562 and HL-60 cells. It is interesting that ASK1 expression
dose-dependently and time-dependently decreased following
treatment with EM23 (Figure 5A). Next, we investigated how
treatment with EM23 affected the phosphorylation statuses of
three different MAPKs (p38, JNK, and ERK1/2) in K562 and
HL-60 cells by western blotting analysis. As shown in Figure 5B
p38 and JNK were time-dependently activated in both cell
lines following treatment with 8 µM EM23. The maximum
activation of JNK by EM23 occurred within 3 h of treatment,
followed by a progressive decline after 6 h (Figure 5B). A similar
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progression of p38 activation was also observed in EM23-treated
K562 cells, while continuous activation of p38 was observed
in EM23-treated HL-60 cells (Figure 5B). K562 and HL-60
cells showed different ERK1/2 phosphorylation profiles following
EM23 treatment (Figure 5B). Treatment of K562 cells with 8 µM
EM23 markedly increased ERK1/2 phosphorylation within 1 h,
followed by sustained activation of ERK1/2 within 12 h. Unlike
in K562 cells, no obvious activation of ERK1/2 was observed
in HL-60 cells treated with EM23 for 12 h (Figure 5B). The
ERK inhibitor FR180204 was further used to clarify the role of
ERK in EM23-mediated apoptosis. As shown in Figure 5C, co-
incubation of EM23 and FR180204 significantly increased the
viability of K562 cells as compared to the cells only treated with
EM23. While there was no obvious change in cellular viability
when HL-60 cells were co-treated with EM23 and FR180204.
These results indicated that MAPK activation might be involved
in EM23-mediated apoptosis.
To further determine whether ROS production can trigger
ASK1 and MAPK activation following EM23 treatment, cells
were pretreated with 5 mM NAC for 1 h and then treated with
EM23 and subjected to western blotting analysis. As shown
in Figures 6A,B, NAC blocked EM23-mediated activation
of ASK1, p38 and JNK in K562 and HL-60 cells. Similarly,
EM23-mediated promotion of ERK1/2 phosphorylation
in K562 cells was significantly suppressed following NAC
pretreatment, while ERK1/2 phosphorylation in HL-60 cells
was unaltered, which was consistent with previous results
(Figure 6B). These results further support the important role
of ROS in EM23-mediated activation of ASK1/MAPK signaling
pathways.
EM23 Suppresses TNF-α-Mediated
NF-κB Activation
Reactive oxygen species interacts with NF-κB signaling pathways
in many ways (Morgan and Liu, 2011). Therefore, we investigated
the effects of EM23 on TNF-α-mediated NF-κB activation via
immunofluorescent staining and western blotting analysis. As
shown in Figure 7A, p65 was primarily distributed throughout
the cytoplasm of the control cells. The addition of TNF-α
caused p65 to undergo nuclear translocation, which was
significantly blocked following EM23 treatment in both K562
and HL-60 cells (Figures 7A,B). Moreover, EM23 treatment
significantly suppressed TNF-α-mediated phosphorylation of
p65 (Figure 7B). In the cytoplasm, TNF-α stimulation decreased
levels of cytoplasmic IκBα, while EM23 treatment significantly
reversed TNF-α-mediated IκBα degradation, although not
completely (Figure 7C). These results indicate that EM23
suppresses TNF-α-mediated NF-κB activation.
Next, we examined the effects of combined treatment with
TNF-α and EM23 on the proliferation of K562 and HL-60 cells
using a CCK-8 assay. As shown in Figure 7D, treating cells with a
combination of TNF-α and EM23 resulted in higher cytotoxicity,
with inhibition rates ranging from 20.0 to 45.2% and from 18.1
to 37.5% in K562 and HL-60 cells, respectively. These results
indicated that EM23 is a potent NF-κB inhibitor and that this
effect is enhanced by TNF-α-mediated cytotoxicity.
FIGURE 6 | NAC reversed EM23-mediated increases in ASK1 and
MAPK phosphorylation. (A) K562 and HL-60 cells were treated with
vehicle, 5 mM NAC, or 8 µM EM23 for 12 h. Cells were also pretreated with
5 mM NAC for 1 h, followed by treatment with 8 µM EM23 for 12 h. Protein
levels of ASK1 and p-ASK1 were analyzed by western blotting. (B) K562 and
HL-60 cells were treated with vehicle, 5 mM NAC, and 8 µM EM23 for 3 h.
Cells were also pretreated with 5 mM NAC for 1 h, followed by treatment with
8 µM EM23 for 3 h. Total protein extracts from treated cells were submitted to
western blotting for detection of p38, p-p38, JNK, p-JNK, ERK1/2, and
p-ERK1/2. β-actin was used as an internal control. All data shown are
representative of three independent experiments.
DISCUSSION
Natural products, in addition to their traditional uses, have
served as important sources of bioactive compounds that have
played significant roles in medical discovery and development
processes (Newman and Cragg, 2012; Wang et al., 2015).
The genus Elephantopus, which belongs to the Asteraceae
family, has recently attracted a great deal of interest due
to its diverse pharmacological activities. Several species of
Elephantopus contained sesquiterpene lactones have been
reported to exert cytotoxicity and possess potential anticancer
activities. Deoxyelephantopin and isodeoxyelephantopin,
two germacranolidese squiterpene lactones, are components
of extracts of Elephantopus scaber L.. Isodeoxyelephantopin
has been reported to suppress NF-κB, potentiate apoptosis,
inhibit invasion and abolish osteoclastogenesis in leukemia
KBM-5 cells (Ichikawa et al., 2006). Deoxyelephantopin was
found to inhibit TS/A tumor growth and lung metastasis
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FIGURE 7 | Continued
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FIGURE 7 | Continued
Inhibitory effects of EM23 on TNF-α-mediated NF-κB activation.
(A) Immunofluorescence analysis of p65 localization. K562 and HL-60 cells
were treated with vehicle or EM23 for 1 h and then stimulated with 1 nM
TNF-α for 30 min. The cells were stained with DAPI (blue), FITC-labeled anti-
p65 antibody (green) and phalloidin (for F-actin labeling, red). All data shown
are representative of three independent experiments. (B) Effects of EM23 on
TNF-α-mediated translocalization and phosphorylation of p65. K562 and HL-
60 cells were co-incubated with 8 µM EM23 and 1 nM TNF-α for the indicated
times. Nuclear extracts were prepared and submitted to western blotting for
the detection of p65 and p-p65. Lamin B1 was used as a loading control. All
data shown are representative of three independent experiments. (C) Effect of
EM23 on TNF-α-mediated degradation of IκBα. K562 and HL-60 cells were
co-incubated with 8 µM EM23 and 1 nM TNF-α for the indicated times.
Cytoplasmic extracts were prepared and submitted to western blotting for the
detection of IκBα. β-actin was used as a loading control. All data shown are
representative of three independent experiments. (D) EM23 enhanced TNF-
α-mediated cytotoxicity. K562 and HL-60 cells were, respectively, incubated
with 4 and 2 µM EM23 for 1 h, followed by treatment with 1 nM TNF-α for
24 h. The cytotoxicity of the combined treatment of EM23 and TNF-α was
detected by CCK-8 assay. All data are presented as the mean ± SD of three
independent experiments. Bars with different characters indicate significant
differences. ∗P < 0.05 and ∗∗P < 0.01 compared to control; #P < 0.05 and
##P < 0.01 compared to TNF-α+EM23.
and double survival time in mice bearing mammary tumors
(Huang et al., 2010). Some of other sesquiterpene lactones
from the other Asteraceae plants, such as thapsigargin,
artemisinin and parthenolide, have also been reported to
have anticancer activities in vivo. Thapsigargin derivation
G-202 is used for treating breast, kidney and prostate cancer
in phase I study (Ghantous et al., 2010). Artemisnin and its
derivations, artesunate and artemether, are being tested in phase
I/II clinical trials for the treatment of breast, colorectal, and
non-small cell lung cancers (Berger et al., 2005; Zhang et al.,
2008). A parthenolide analog dimethylamino-parthenolide is
now in clinical phase I against AML, ALL, and other blood
cancers (Guzman et al., 2007; Ghantous et al., 2010). These
findings provide clues for potential therapeutic application of
EM23 as anti-leukemia agents in clinic. It is worthy further
investigating the effect of EM23 on AML and CML in vivo in
next study.
Apoptosis, a programmed form of cell death, involves the
degradation of cellular constituents by a group of cysteine
proteases called caspases. Caspase activation occurs through
two main molecular pathways, known as the extrinsic
and the intrinsic apoptotic pathways (Burgess, 2013). The
intrinsic apoptotic pathway is characterized by mitochondrial
permeabilization, causing the release of pro-apoptotic proteins
into the cytosol (Matsuzawa and Ichijo, 2008). Indeed, we found
that EM23 significantly decreased 1ψm in K562 and HL-60
cells (Figure 3A) and up-regulated caspase signaling cascades
(caspases 9 and 3), which resulted in the activation of the
downstream cellular death substrate PARP (Figure 2C). These
findings indicate that EM23 may induce apoptosis through the
intrinsic apoptotic pathway.
Excessive intracellular production of ROS is known to
induce apoptosis (Sabharwal and Schumacker, 2014). The
FIGURE 8 | EM23 mediation of intracellular signaling leading to apoptosis in human myeloid leukemia cells. Key: black arrows, activation; black blocks,
inhibition; double arrows, multiple signal transduction steps.
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mitochondrial respiratory chain (electron transport complexes)
is a major source of intracellular ROS generation (Sabharwal and
Schumacker, 2014). In the current study, EM23 induced obvious
mitochondrial dysfunction and markedly increased intracellular
ROS levels in K562 and HL-60 cells. Cellular ROS generation
played a vital role in EM23-mediated apoptosis and accumulation
of cells in G2/M or S phase in both cell lines, and co-treatment
with EM23 and the reducing agent NAC, which quenches ROS,
almost completely reversed these effects (Figure 4). These results
indicate that EM23-mediated apoptosis in K562 and HL-60 cells
might be governed by ROS-mediated mechanisms.
The Trx system, a ubiquitous oxidoreductase system that
is overexpressed in various tumor types, has important roles
in reducing enzymes and maintaining intracellular protein
thiol redox balance (Fink et al., 2015). The mammalian TrxR
protein contains a highly reactive active selenocysteine residue
that is susceptible to electrophilic compounds and has been
identified as a novel chemotherapeutic target for anticancer drug
development (Liu et al., 2014). Recent studies have revealed
that redox-regulating mechanisms, such as the Trx system,
represent important targets for the treatment of malignancies
(Trachootham et al., 2009). Disruption of the Trx system by
EM23 may interfere with intracellular redox balance and lead to
the accumulation of ROS, which subsequently initiates apoptosis
in K562 and HL-60 cells.
Trx target proteins are involved in various specific pathways
associated with the regulation of apoptosis. ASK1, a MAPKKK
family member, is tightly controlled by Trx and acts as a major
contributor in regulating ROS-mediated apoptosis through the
activation of the JNK and p38 signaling pathways (Seong et al.,
2015). Our results demonstrated that EM23 treatment increased
the phosphorylation of ASK1 at Thr845 (Figure 5A), which
further phosphorylated the downstream MAPKs JNK and p38
(Figure 5B), suggesting that EM23 may activate the ASK1-
JNK/p38 signaling axis in a ROS-dependent manner to exert
its pro-apoptotic effects. In addition, following co-treatment
with EM23 and NAC, the phosphorylation levels of ASK1,
p38 and JNK were notably lower than those following EM23
treatment alone (Figure 6). These results are consistent with
the full reversion of EM23-mediated apoptosis that was found
following pretreatment with NAC. Our results indicated that
EM23-mediated ROS accumulation was an important signaling
intermediate in ASK1-dependent apoptosis.
It has been well established that increases in ROS levels
are effective inducers of MAPK-mediated apoptosis (Finkel
and Holbrook, 2000). As shown in Figure 6B, downstream
MAPK (p38, JNK and ERK1/2) pathways became activated
following EM23 treatment in K562 cells. In HL-60 cells,
treatment with EM23 also led to significant activation of
p38 and JNK; however, there was no obvious increase in
ERK1/2 phosphorylation during the treatment (Figure 6B).
Our results are in agreement with other studies reporting that
compounds that cause ROS generation do not necessarily lead
to increases in ERK1/2 phosphorylation in treated HL-60 cells
(Uen et al., 2007; Wang et al., 2014). It is well documented
that the activation of ERK1/2 generally promotes cell survival.
However, depending on cell type and stimulus, ERK1/2 also can
mediate pro-apoptotic functions (Cagnol and Chambard, 2010;
Li et al., 2013). Our results indicated that ERK1/2 activation
in K562 cells may contribute to EM23-mediated apoptosis
(Figure 5C).
NF-κB, one of major chemoresistance-related anti-apoptotic
factors (Yip et al., 2011), is frequently up-regulated in human
chronic and AML (Hsieh and Van Etten, 2014). Trx plays dual
and opposing roles in the regulation of NF-κB: in the cytoplasm,
Trx blocks IκBα degradation, thereby inhibiting NF-κB activation
(Takeuchi et al., 2000), whereas in the nucleus Trx enhances
NF-κB transcriptional activity by enhancing its ability to bind
DNA (Hirota et al., 1999; Ueno et al., 2007). In the current
study, it is possible that EM23 inhibited the NF-κB pathway
by inhibiting the Trx system. Moreover, small molecules that
mimic EM23 by simultaneously activating ROS-MAPK pro-
apoptotic pathways and blocking anti-apoptotic NF-κB pathways
may improve the outcomes of myeloid leukemia chemotherapy.
In summary, we showed the ability of EM23 to inhibit the
proliferation of human myeloid leukemia K562 and HL-60 cells
by inducing apoptosis via mitochondrial pathways. Suppression
of the Trx system following treatment with EM23 could result
in ROS accumulation and subsequently activate a number of
Trx-dependent pathways, including the ASK1, p38, JNK and
ERK MAPK pathways, which may contribute to EM23-mediated
apoptosis (Figure 8). Furthermore, EM23 also effectively blocks
TNF-α/NF-κB axis signaling, implying that EM23 has a potential
role in preventing NF-κB-mediated anti-apoptotic pathways.
This report represents the first comprehensive analysis of the
cellular signaling events that are affected by treatment with EM23,
a compound found in EM, in human myeloid leukemia cells.
The findings contained here in detail a possible anticarcinogenic
molecular mechanism for EM23.
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